Labiotech.eu

News and Trends 5 Oct 2017

Spanish Biotech’s Stock Surges After Decision to Move out of Barcelona

Oryzon Genomics announced it will move its headquarters from Barcelona to Madrid days after the Catalonian independence vote, making its stock grow by 30%. Oryzon Genomics, a Spanish biotech leveraging epigenetics to treat cancer, announced on Tuesday its decision to move out of Barcelona and establish its new headquarters in Madrid, citing the “optimization of […]

October 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 5 Oct 2017

British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology

Angle will raise £12.2M, which will allow it to acquire assets from Axela to put the finishing touches to its full liquid biopsies solution. Angle is a leader in the liquid biopsy market, the ‘holy grail’ of cancer diagnostics. The company has developed technology that recently outperformed the gold standard in the field. Angle is hoping to raise £12.2M […]

October 5, 2017 - 3 minutesmins - By Alex Dale

fecal transplant diabetes netherlands2 1

News and Trends 5 Oct 2017

Dutch Clinical Trial Points to Fecal Transplant as Diabetes Treatment

A small clinical trial in the Netherlands has found that a fecal transplant from a lean donor can temporarily improve diabetes symptoms in obese men. Research published in Cell Metabolism from the University of Amsterdam has found that a fecal transplant from lean men to obese men can cause a short-term improvement in insulin resistance. This […]

October 5, 2017 - 3 minutesmins - By Alex Dale

Nobel Prize in Chemistry 2017 Richard Henderson Heptares Therapeutics

News and Trends 5 Oct 2017

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This year’s Nobel Prize in Chemistry has been awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy. This technology, now widely used in structural biology labs, is considered a stepping […]

October 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2017

Synbio adds Softness: Robots of the Future will be Squishy

As AI and machine learning approach biotech, synthetic biology is approaching soft robotics. What is it bringing to the field? Conventional rigid-bodied robots are used to perform specific single tasks efficiently but often with limited adaptability when it comes to interacting with humans. During the past few years, soft robots made of highly pliable materials […]

October 5, 2017 - 5 minutesmins - By External Contributor

News and Trends 4 Oct 2017

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […]

October 4, 2017 - 2 minutesmins - By Alex Dale

immatics amgen fundraising cancer immunotherapy

News and Trends 4 Oct 2017

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

myovant science uterine fibroids treatment

News and Trends 4 Oct 2017

Oral Drug to Treat Uterine Fibroids Boasts Phase III Success

Myovant’s partner Takeda has reported Phase III results showing relugolix to be more effective in treating uterine fibroids than existing hormonal therapy. Myovant has announced positive results from its lead candidate, relugolix, which showed itself to be better than leuprorelin injections — a common first-line treatment — at reducing menstrual bleeding in a Phase III trial in patients […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 2 Oct 2017

CRISPR Gets Snubbed Again by the Nobel Prize Committee

The Nobel Prize Committee has made CRISPR wait at least one more year, as it was pipped by research into the mechanisms underlying circadian rhythm. The 2017 Nobel Prize in Physiology or Medicine has been awarded to Jeffrey C. Hall, Michael Rosbash and Michael W. Young. There had been whispers that CRISPR would take home the prize, but the […]

October 2, 2017 - 3 minutesmins - By Alex Dale

More News! 2 Oct 2017

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects

Swedish Gesynta Pharma has signed an agreement with Orexo to acquire a drug candidate to treat inflammatory diseases with fewer side effects. Based in Uppsala, Orexo has built a solid pipeline since its foundation in 1995, including three products currently in the market. The company has now struck a deal for one of its early-stage programs, OX-MPI, focused on inflammation. BI1029539, the […]

October 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Oct 2017

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […]

October 2, 2017 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Spanish Biotech’s Stock Surges After Decision to Move out of Barcelona

British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology

Dutch Clinical Trial Points to Fecal Transplant as Diabetes Treatment

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Synbio adds Softness: Robots of the Future will be Squishy

Ablynx Launches $175M IPO on Wall Street After Phase III Success

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Oral Drug to Treat Uterine Fibroids Boasts Phase III Success

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

CRISPR Gets Snubbed Again by the Nobel Prize Committee

New Swedish Pharma Bids for Anti-Inflammatory Drugs Without Side Effects

Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!